Tompkins Financial Corp Has $5.22 Million Position in Johnson & Johnson (NYSE:JNJ)

Tompkins Financial Corp decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 32,197 shares of the company’s stock after selling 1,361 shares during the period. Tompkins Financial Corp’s holdings in Johnson & Johnson were worth $5,218,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new stake in Johnson & Johnson in the 1st quarter valued at $765,000. Noesis Capital Mangement Corp lifted its holdings in shares of Johnson & Johnson by 21.3% during the first quarter. Noesis Capital Mangement Corp now owns 8,031 shares of the company’s stock worth $1,270,000 after buying an additional 1,410 shares in the last quarter. Keener Financial Planning LLC boosted its position in shares of Johnson & Johnson by 42.1% in the first quarter. Keener Financial Planning LLC now owns 361 shares of the company’s stock valued at $58,000 after acquiring an additional 107 shares during the period. SPC Financial Inc. increased its position in Johnson & Johnson by 2.7% during the first quarter. SPC Financial Inc. now owns 17,008 shares of the company’s stock worth $2,690,000 after acquiring an additional 441 shares during the period. Finally, Hemenway Trust Co LLC raised its stake in Johnson & Johnson by 1.2% in the 1st quarter. Hemenway Trust Co LLC now owns 212,169 shares of the company’s stock worth $33,563,000 after purchasing an additional 2,435 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on JNJ. TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Citigroup upped their target price on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Morgan Stanley lifted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, TD Cowen reduced their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $175.00.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.8 %

Shares of NYSE JNJ opened at $155.47 on Friday. The company has a 50 day simple moving average of $162.61 and a 200 day simple moving average of $155.81. The firm has a market cap of $374.31 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 2.80 and a beta of 0.53. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $2.66 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.19%. Johnson & Johnson’s payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.